by Karolinska Institutet Systemic antibody responses, inflammation markers and other clinical parameters in relation to COVID-19 severity during acute disease. (A) Plasma IgG and IgA responses (n=19 for mild, n=58 for moderate, n=58 for severe and n=12 for fatal) against N, S and RBD are shown together with the levels of (B) C-reactive protein and the...
by Samantha Bochenek, University of Kentucky Credit: Pixabay/CC0 Public Domain Monoclonal antibody therapy is an infusion treatment that can reduce the severity of COVID-19. Here are some of the commonly asked questions about the treatment. Q: What are monoclonal antibodies and how do they work? A: Monoclonal antibodies are proteins created in a lab. The proteins mimic your...
by Ola Nilsson, Umea University Fig. 1. Cumulative incidence and 95% confidence intervals for symptomatic Covid-19 infection in individuals given a heterologous ChAdOx1 nCoV-19 / BNT162b2 schedule and in corresponding controls. Credit: DOI: 10.1016/j.lanepe.2021.100249 People who had received a first dose of the Oxford-AstraZeneca COVID-19 vaccine and received an mRNA vaccine for their second dose had...
By Rich Haridy October 10, 2021 The gene variant plays a role in heightened inflammatory responses influencing both Alzheimer’s disease and severe COVID-19steilemas/Depositphotos Early in the pandemic researchers saw disproportionately high rates of dementia patients suffering from severe COVID-19. A common hypothesis was that memory impairments associated with neurodegeneration affect a person’s ability to consistently...
by Ana Gajic, St. Michael’s Hospital Graphical abstract. Credit: DOI: 10.1136/bmj.n2400 A high dose of an inexpensive and globally available blood-thinning medication reduces the risk of death in hospitalized patients who are moderately ill with COVID-19, suggests a new study led by St. Michael’s Hospital. Published today in the BMJ, the international RAPID Trial compared the effects...
Karen Weintraub Elizabeth Weise USA TODAY A federal advisory panel voted Thursday to support booster shots of the Moderna COVID-19 vaccine for people 65 and up, as well as younger adults with certain medical problems or jobs that put them at increased risk for infection. The booster shot will be a half-dose of the same...
UNIVERSITY OF CALIFORNIA – SAN DIEGO IMAGE: ALESSANDRA FRANCO, MD, PH.D., ASSOCIATE PROFESSOR OF PEDIATRICS AT UC SAN DIEGO SCHOOL OF MEDICINE. CREDIT: UC SAN DIEGO HEALTH SCIENCES Multisystem inflammatory syndrome in children (MIS-C) is a serious condition associated with a recent COVID-19 infection. The syndrome is rare, and it remains unclear how the viral...
by Andy Fell, UC Davis Credit: Pixabay/CC0 Public Domain One-third of recovered COVID-19 patients reported new or continuing symptoms two months after their positive tests, according to a study by graduate students in epidemiology at the University of California, Davis, in collaboration with the Long Beach Department of Health and Human Services. Women, people over 39,...
by University of Bristol Credit: Unsplash/CC0 Public Domain Research has found that it is safe for people to receive a flu vaccine at the same time as a COVID-19 vaccine. Reported side effects were mainly mild to moderate, and there were no negative impacts on the immune response produced by either vaccine when both were given on...
By Emily Henderson, B.Sc. Sep 29 2021 Researchers at the University of East Anglia and James Paget University Hospital are launching a new project to see whether Vitamin A could help people regain their sense of smell after viral infections including COVID-19. We also spoke exclusively to Professor Carl Philpott who is leading the study to find...
